These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35334061)

  • 1. "SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment.
    Patoulias D; Papadopoulos C; Doumas M
    Intern Emerg Med; 2022 Aug; 17(5):1553-1554. PubMed ID: 35334061
    [No Abstract]   [Full Text] [Related]  

  • 2. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis.
    Cuddy SAM
    Circ Heart Fail; 2022 Jul; 15(7):e009387. PubMed ID: 35766044
    [No Abstract]   [Full Text] [Related]  

  • 4. Kidney involvement in transthyretin cardiac amyloidosis - Role of urinary albumin to creatinine ratio and need for further evidence generation.
    Khan MS; Sperry BW; Butler J
    Eur J Heart Fail; 2024 Jan; 26(1):74-76. PubMed ID: 38191996
    [No Abstract]   [Full Text] [Related]  

  • 5. New challenges in the management of patients with transthyretin cardiac amyloidosis: beyond oral anticoagulation.
    de Frutos F; Gonzalez-Lopez E
    Rev Esp Cardiol (Engl Ed); 2023 Jul; 76(7):494-496. PubMed ID: 36716993
    [No Abstract]   [Full Text] [Related]  

  • 6. Amyloid transthyretin cardiac amyloidosis with different manifestations, test findings and types.
    Budweg J; Al-Ani M; Assaf Y; Parker A; Aranda J
    BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37080632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Baldovino S; Costanzo P; Roccatello D
    Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
    [No Abstract]   [Full Text] [Related]  

  • 8. Transthyretin Cardiac Amyloidosis: From Rare Monogenic Disease to Common Pathway in Heart Failure?
    Culotta V; Moon JC
    Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):888-889. PubMed ID: 27514622
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac transthyretin/leukocyte chemotactic factor (LECT) 2 double amyloidosis in a patient suffering from heart failure.
    Greulich S; Mahrholdt H; Casadonte R; Steinmüller-Magin L; Latus J; Blessing F; Kriegsmann J; Bekeredjian R; Gawaz M; Klingel K
    Clin Res Cardiol; 2023 Mar; 112(3):444-449. PubMed ID: 35925392
    [No Abstract]   [Full Text] [Related]  

  • 10. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series.
    Zampieri M; Argirò A; Allinovi M; Perfetto F; Cappelli F
    Intern Emerg Med; 2022 Jun; 17(4):1243-1245. PubMed ID: 35137306
    [No Abstract]   [Full Text] [Related]  

  • 11. Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival.
    Tubben A; Nienhuis HLA; van der Meer P
    Eur J Heart Fail; 2023 Nov; 25(11):2065-2066. PubMed ID: 37792736
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity.
    Lee YZJ; Fajardo J; Brown E; D'Adamo CR; Judge DP
    J Cardiovasc Transl Res; 2022 Aug; 15(4):689-691. PubMed ID: 35083733
    [No Abstract]   [Full Text] [Related]  

  • 14. Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
    Stein AP; Matthia EL; Petty SA; Stewart B; Vilaro JR; Al-Ani MAZ; Ahmed MM; Aranda JM; Hiemenz JW; Parker AM
    Am J Cardiol; 2024 Jan; 210():85-92. PubMed ID: 37852567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatments of AL and ATTR amyloidosis.
    Chandrashekar P; Desai AK; Trachtenberg BH
    Heart Fail Rev; 2022 Sep; 27(5):1587-1603. PubMed ID: 34783948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials.
    Cheng RK; Maurer MS
    JACC Heart Fail; 2021 Nov; 9(11):803-806. PubMed ID: 34509407
    [No Abstract]   [Full Text] [Related]  

  • 17. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
    Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
    Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
    [No Abstract]   [Full Text] [Related]  

  • 18. Multimodality imaging of simultaneous occurrence of cardiac transthyretin amyloidosis and cardiac sarcoidosis.
    Elchinova E; Banz Y; Zbinden S; Caobelli F; Gräni C
    J Nucl Cardiol; 2023 Oct; 30(5):2207-2208. PubMed ID: 35974261
    [No Abstract]   [Full Text] [Related]  

  • 19. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 20. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.